Contrasting Compass Pathways (NASDAQ:CMPS) & Ascendant Solutions (OTCMKTS:MYDP)

Compass Pathways (NASDAQ:CMPS) and Ascendant Solutions (OTCMKTS:MYDP) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, profitability and risk.

Earnings and Valuation

This table compares Compass Pathways and Ascendant Solutions”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86 million	($3.09)	-3.04
Ascendant Solutions	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Compass Pathways and Ascendant Solutions’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-192.95%	-61.31%
Ascendant Solutions	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings for Compass Pathways and Ascendant Solutions, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1	1	7	2	2.91
Ascendant Solutions	0	0	0	0	0.00

Compass Pathways presently has a consensus target price of $20.55, indicating a potential upside of 118.80%. Given Compass Pathways’ stronger consensus rating and higher possible upside, research analysts plainly believe Compass Pathways is more favorable than Ascendant Solutions.

Insider & Institutional Ownership

46.2% of Compass Pathways shares are held by institutional investors. 2.8% of Compass Pathways shares are held by insiders. Comparatively, 31.6% of Ascendant Solutions shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Compass Pathways beats Ascendant Solutions on 5 of the 8 factors compared between the two stocks.

About Compass Pathways

Compass Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to Compass Pathways plc in August 2020. Compass Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

About Ascendant Solutions

Dougherty's Pharmacy, Inc. focuses on acquiring, managing, and growing community based pharmacies in the Southwest Region of the United States. Its flagship store is Dougherty's Pharmacy, a turn-key multi-service pharmacy located in Dallas, Texas. The company was formerly known as Ascendant Solutions, Inc. and changed its name to Dougherty's Pharmacy, Inc. in May 2017. Dougherty's Pharmacy, Inc. was founded in 1929 and is based in Dallas, Texas.